Keidel Sarah, McColl Aubretia, Edmonds Sally
Department of Rheumatology, Stoke Mandeville Hospital, Aylesbury, UK.
BMJ Case Rep. 2011 Dec 21;2011:bcr1020114935. doi: 10.1136/bcr.10.2011.4935.
Relapsing polychondritis and Sweet's syndrome are rare systemic inflammatory conditions. The authors present a patient who developed Sweet's syndrome 1 week after adalimumab therapy for refractory relapsing polychondritis. Coexistent relapsing polychondritis and Sweet's syndrome is rare, however, is likely to represent a true disease association and signifies a high risk of myelodysplasia. Antitumour necrosis factor α (TNFα) therapy is a treatment option in both relapsing polychondritis and Sweet's syndrome, and switching anti-TNFα agents may be feasible in the event of adverse reaction.
复发性多软骨炎和Sweet综合征是罕见的全身性炎症性疾病。作者报告了一名难治性复发性多软骨炎患者，在接受阿达木单抗治疗1周后出现了Sweet综合征。复发性多软骨炎和Sweet综合征同时存在的情况罕见，但可能代表一种真正的疾病关联，提示骨髓发育异常的高风险。抗肿瘤坏死因子α（TNFα）治疗是复发性多软骨炎和Sweet综合征的一种治疗选择，出现不良反应时更换抗TNFα药物可能可行。
